- Home
- ASR vs RGEN Comparison
ASR vs RGEN Comparison
Compare ASR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASR
- RGEN
- Stock Information
- Founded
- ASR 1996
- RGEN 1981
- Country
- ASR Mexico
- RGEN United States
- Employees
- ASR N/A
- RGEN N/A
- Industry
- ASR Aerospace
- RGEN Medical/Dental Instruments
- Sector
- ASR Consumer Discretionary
- RGEN Health Care
- Exchange
- ASR Nasdaq
- RGEN Nasdaq
- Market Cap
- ASR 8.0B
- RGEN 7.6B
- IPO Year
- ASR 2000
- RGEN N/A
- Fundamental
- Price
- ASR $272.25
- RGEN $160.51
- Analyst Decision
- ASR Buy
- RGEN Buy
- Analyst Count
- ASR 2
- RGEN 12
- Target Price
- ASR $326.00
- RGEN $187.44
- AVG Volume (30 Days)
- ASR 54.5K
- RGEN 497.0K
- Earning Date
- ASR 02-24-2025
- RGEN 02-19-2025
- Dividend Yield
- ASR 6.54%
- RGEN N/A
- EPS Growth
- ASR 23.91
- RGEN N/A
- EPS
- ASR 2.16
- RGEN N/A
- Revenue
- ASR $1,490,558,036.00
- RGEN $633,513,000.00
- Revenue This Year
- ASR $17.61
- RGEN $2.28
- Revenue Next Year
- ASR $18.87
- RGEN $9.88
- P/E Ratio
- ASR $12.39
- RGEN N/A
- Revenue Growth
- ASR 11.33
- RGEN N/A
- 52 Week Low
- ASR $248.88
- RGEN $113.50
- 52 Week High
- ASR $357.90
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- ASR 57.91
- RGEN 62.61
- Support Level
- ASR $255.90
- RGEN $150.23
- Resistance Level
- ASR $267.46
- RGEN $160.64
- Average True Range (ATR)
- ASR 6.52
- RGEN 6.76
- MACD
- ASR 1.20
- RGEN 1.14
- Stochastic Oscillator
- ASR 83.15
- RGEN 80.27
About ASR Grupo Aeroportuario del Sureste S.A. de C.V.
Grupo Aeroportuario del Sureste SAB de CV operates airports in southeast Mexico. The company's segments include Cancun; Aerostar; Airplan; Merida; Villahermosa; Holding and Services and other. It generates maximum revenue from the Cancun segment.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.